Puma Biotechnology, Inc.
PBYI
$3.01
-$0.03-0.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -22.12% | -26.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -22.12% | -26.65% | |||
| Cost of Revenue | -24.17% | -52.16% | |||
| Gross Profit | -21.49% | -12.22% | |||
| SG&A Expenses | 5.91% | -1.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.07% | -21.81% | |||
| Operating Income | -70.19% | -39.47% | |||
| Income Before Tax | -73.30% | -40.62% | |||
| Income Tax Expenses | 104.15% | -2,528.52% | |||
| Earnings from Continuing Operations | -84.59% | -4.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -84.59% | -4.98% | |||
| EBIT | -70.19% | -39.47% | |||
| EBITDA | -58.16% | -35.06% | |||
| EPS Basic | -84.74% | -5.16% | |||
| Normalized Basic EPS | -73.56% | -40.72% | |||
| EPS Diluted | -84.74% | -4.10% | |||
| Normalized Diluted EPS | -73.58% | -40.89% | |||
| Average Basic Shares Outstanding | 1.02% | 0.18% | |||
| Average Diluted Shares Outstanding | 1.01% | 0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||